Mahdieh Mahboobi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mahdieh Mahboobi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Hamid Sedighian
Applied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
4 shared publications - Abolfazl Jahangiri
Applied Microbiology Research Center, Biomedicine Technologies Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran
1 shared publication - Amir Razavinia
Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
1 shared publication - Antoni Miecznikowski
Department of Fermentation Technology, Prof. Wacław Dąbrowski Institute of Agricultural and Food Biotechnology-State Research Institute, Rakowiecka 36 Street, 02-532 Warsaw, Poland
1 shared publication - Arezoo Fallah
Department of Bacteriology and Virology, Faculty of Medicine, Isfahan University of Medical sciences, Isfahan, Iran
1 shared publication - Arezoo Gowhari Shabgah
School of Medicine Bam University of Medical Sciences Bam Iran
1 shared publication
Latest Publications
- Open Access
- 3 February 2026
- Published by Elsevier in Current Research in Structural Biology
- Vol. 11, 100180
Decoding the impact of nsSNP variants on BCL6 function through integrated computational analysis
- 3 February 2026
- Published by Elsevier in Current Research in Structural Biology
- Vol. 11, 100180
Open AccessDecoding the impact of nsSNP variants on BCL6 function through integrated computational analysis
- Open Access
- 12 August 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (8)
The relationship between respiratory tract infections caused by toxin-producing bacteria in burn patients during COVID-19: pathogenesis, diagnostics and novel therapies
Graphical Schematic overview of COVID-19–associated bacterial co-infections in burn patients. Burn-related skin barrier damage, immunosuppression, and prolonged hospitalization increase susceptibility to pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa during SARS-CoV-2 infection.
- 12 August 2025
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 74 (8)
Open AccessThe relationship between respiratory tract infections caused by toxin-producing bacteria in burn patients during COVID-19: pathogenesis, diagnostics and novel therapies
Graphical Schematic overview of COVID-19–associated bacterial co-infections in burn patients. Burn-related skin barrier damage, immunosuppression, and prolonged hospitalization increase susceptibility to pathogens such as Staphylococcus aureus and Pseudomonas aeruginosa during SARS-CoV-2 infection.
- Open Access
Engineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study
The cytolethal distending toxin (CDT), Haemophilus ducreyi, is one of the bacterial toxins that have recently been considered for targeted therapies, especially in cancer therapies. CDT is an A-B2 exotoxin. Its catalytic subunit (CdtB) is capable of inducing DNA double strand breaks, cell cycle arrest and apoptosis in host eukaryotic cells. The sequence alignment indicates that the CdtB is structurally homologyr to phosphatases and deoxyribonucleases I (DNase I). Recently, it has been found that CdtB toxicity is mainly related to its nuclease activity. The immunogenicity of CDT can reduce its effectiveness in targeted therapies. However, the toxin can be very useful if its immunogenicity is significantly reduced. Detecting hotspot ectopic residues by computational servers and then mutating them to eliminate B-cell epitopes is a promising approach to reduce the immunogenicity of foreign protein-based therapeutics. By the mentioned method, in this study, we try to reduce the immunogenicity of the CdtB- protein sequence. This study initially screened residue of the CdtB is B-cell epitopes both linearly and conformationally. By overlapping the B-cell epitopes with the excluded conserve residues, and active and enzymatic sites, four residues were allowed to be mutated. There were two mutein options that show reduced antigenicity probability. Option one was N19F, G74I, and S161F with a VaxiJen score of 0.45 and the immune epitope database (IEDB) score of 1.80, and option two was N19F, G74I, and S161W with a VaxiJen score of 0.45 and IEDB score of 1.88. The 3D structure of the proposed sequences was evaluated and refined. The structural stability of native and mutant proteins was accessed through molecular dynamic simulation. The results showed that the mutations in the mutants caused no considerable changes in their structural stability. However, mutant 1 reveals more thermodynamic stability during the simulation. The applied approaches in this study can be used as rough guidelines for finding hot spot immunogen regions in the therapeutic proteins. Our results provide a new version of CdtB that, due to reduced immunogenicity and increased stability, can be used in toxin-based drugs such as immunotoxins.
Open AccessEngineering of Cytolethal Distending Toxin B by Its Reducing Immunogenicity and Maintaining Stability as a New Drug Candidate for Tumor Therapy; an In Silico Study
The cytolethal distending toxin (CDT), Haemophilus ducreyi, is one of the bacterial toxins that have recently been considered for targeted therapies, especially in cancer therapies. CDT is an A-B2 exotoxin. Its catalytic subunit (CdtB) is capable of inducing DNA double strand breaks, cell cycle arrest and apoptosis in host eukaryotic cells. The sequence alignment indicates that the CdtB is structurally homologyr to phosphatases and deoxyribonucleases I (DNase I). Recently, it has been found that CdtB toxicity is mainly related to its nuclease activity. The immunogenicity of CDT can reduce its effectiveness in targeted therapies. However, the toxin can be very useful if its immunogenicity is significantly reduced. Detecting hotspot ectopic residues by computational servers and then mutating them to eliminate B-cell epitopes is a promising approach to reduce the immunogenicity of foreign protein-based therapeutics. By the mentioned method, in this study, we try to reduce the immunogenicity of the CdtB- protein sequence. This study initially screened residue of the CdtB is B-cell epitopes both linearly and conformationally. By overlapping the B-cell epitopes with the excluded conserve residues, and active and enzymatic sites, four residues were allowed to be mutated. There were two mutein options that show reduced antigenicity probability. Option one was N19F, G74I, and S161F with a VaxiJen score of 0.45 and the immune epitope database (IEDB) score of 1.80, and option two was N19F, G74I, and S161W with a VaxiJen score of 0.45 and IEDB score of 1.88. The 3D structure of the proposed sequences was evaluated and refined. The structural stability of native and mutant proteins was accessed through molecular dynamic simulation. The results showed that the mutations in the mutants caused no considerable changes in their structural stability. However, mutant 1 reveals more thermodynamic stability during the simulation. The applied approaches in this study can be used as rough guidelines for finding hot spot immunogen regions in the therapeutic proteins. Our results provide a new version of CdtB that, due to reduced immunogenicity and increased stability, can be used in toxin-based drugs such as immunotoxins.
- 30 December 2014
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 11 (3) , 1167-1178
Immunotherapy as an Optimal Manner in Cancer Treatment (Review Article)
Biological Sciences, Health Sciences,Biology,Food and Medicinal control laboratories
- 30 December 2014
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 11 (3) , 1167-1178
Immunotherapy as an Optimal Manner in Cancer Treatment (Review Article)
Biological Sciences, Health Sciences,Biology,Food and Medicinal control laboratories
- 30 September 2014
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 11 (2) , 469-477
Virulence Factor Diversity Between Imipenem Resistant and Imipenem Susceptible Strains of Escherichia coli Isolated from Hospitalized Patients with Severe Urinary Tract Infections
- 30 September 2014
- Published by Oriental Scientific Publishing Company in Biosciences Biotechnology Research Asia
- Vol. 11 (2) , 469-477
Virulence Factor Diversity Between Imipenem Resistant and Imipenem Susceptible Strains of Escherichia coli Isolated from Hospitalized Patients with Severe Urinary Tract Infections